Klin Onkol 2005; 18(3): 89-91.
Summary: Chemotherapy has been studied extensively in advanced prostate cancer, especially in the hormone-refractory prostate cancer (HRCP) setting. Docetaxel is currently among the most active agents for managing HRCP. In phase II trials, single-agent docetaxel induced PSA response (≧ 50 % decline of PSA, range 41%-64%) in 42% of treated men. In these trials, weekly administration of docetaxel appeared to be better tolerated than the 3-week dosing regimen, producing less neutropenia. Patients, methods and results: Thirty-two patients were treated with docetaxel 40 mg/m2, repeated weekly for 6 weeks of an 8-week cycle. Seventeen of 32 patients achieved ≧ 50 % decline of PSA, eight of 32 patients achieved ≧ 25 % decline of PSA. Time to progression of PSA levels was 22 weeks and median survival of 20 patients was 16.8 months. Toxicity was moderate, with following grade 3/4 toxicities: nail toxicity, alopecia.
